GlassScriptPhysician profile
Emily Rose Anodide
NPI 1346084803
$1,303.90
in general payments reported to CMS, 2019-2025
19 companies · $907 in 2025
The $907 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $397 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,204 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.91 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $269.78 | 2025 | Tremfya |
| Leo Pharma INC. | $178.19 | 2025 | Anzupgo |
| Abbvie INC. | $130.78 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $116.91 | 2024-2025 | Unithroid |
| Novo Nordisk INC | $86.34 | 2024-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $80.15 | 2024-2025 | |
| Lilly USA, LLC | $75.54 | 2025 | Mounjaro, Jardiance, Zepbound |
| Ascendis Pharma Endocrinology INC | $46.58 | 2025 | Yorvipath |
| Antares Pharma, INC. | $41.85 | 2024 | Xyosted |
| Incyte Corporation | $40.65 | 2025 | Opzelura |
| Madrigal Pharmaceuticals | $38.14 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $34.74 | 2025 | |
| Recordati_rare_diseases_inc. | $27.98 | 2024 | Isturisa, Signifor Lar |
| Sanofi-Aventis U.S. LLC | $27.95 | 2025 | |
| Esperion Therapeutics, INC. | $24.01 | 2024 | Nexletol |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $22.55 | 2025 | |
| Medtronic, INC. | $21.86 | 2024 | Minimed 780g |
| Verity Pharmaceuticals INC. | $19.98 | 2024 | Tlando |
| Mannkind Corporation | $19.92 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Anodide listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.